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Cystic Fibrosis (CF) is the most commonly inherited, life-shortening genetic condition amongst 
Caucasians, with an incidence of about 1 in 3,800 newborns and currently affecting about 30,000 
Americans.  It is chronically debilitating and the annual cost of medical care per person makes it  
a serious public health concern.  Airway inflammation contributes to progressive pulmonary 
disease, the leading cause of morbidity and mortality in patients with Cystic Fibrosis.  The 
mechanism by which the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene 
affects airway inflammation has not been fully elucidated to date; however, several mechanisms 
have been proposed.  Despite the need for continued study in determining this mechanism, we do 
know that mutations in the CFTR gene ultimately result in bacterial colonization in the lungs, 
reduced mucociliary clearance and airway inflammation.  Chronic airway inflammation results in 
continued assault on the lungs and progresses the course of the disease.  Airway inflammation 
can be monitored through the use of bronchoalveolar lavage to evaluate the influx of neutrophils; 
however, routine bronchoscopy is an invasive procedure and is less than ideal for routine 
assessment.  Exhaled gas as a marker for airway inflammation is useful in that it is minimally 
invasive and relatively easy to obtain.  Some of the data on the clinical utility of exhaled gas 
measurements has been conflicting with regard to its efficacy in assessing airway inflammation.  
If exhaled gas measurements can be used to assess airway inflammation, they could provide a 
non-invasive alternative to monitor inflammation and do so more frequently than invasive 
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methods, with the ultimate goal of being able to detect inflammation earlier with the intent of 
earlier treatment and possible reduction in progression of lung disease. 
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1.0  INTRODUCTION 
This literature review of research that has been conducted on the use of exhaled gas as a 
non-invasive marker of airway inflammation in patients with Cystic Fibrosis (CF) is 
supplemental to a much larger project studying the use of exhaled gas in patients with CF. The 
primary project is a three-phase study that is currently underway and involves the continuous 
collection of exhaled gas measurements as well as sputum cultures in order to provide more 
information on inflammatory markers in patients with CF.  This data is still being collected and 
further research is needed in order to produce preliminary results. In order to more fully 
understand the relevance of using non-invasive markers to assess airway inflammation, it is 
important to understand what the disease is and how mutations in the CFTR gene cause the 
disease as well as the inflammatory process.  The diagnosis, progression, management, genetics 
and inheritance of CF will be discussed with special attention on the role of airway inflammation 
in the progression of lung disease.  The need for monitoring airway inflammation to better 
manage the disease will also be emphasized.  Studies looking at the clinical utility of using non-
invasive exhaled gas measurements to assess airway inflammation in CF have not been 
extensively studied, so this project was designed to highlight the most relevant or substantial 
research currently available.      
   Cystic Fibrosis (CF), also called Mucoviscidosis, is often described as the most common, 
lethal, genetic condition in Caucasians.  It is a chronic, progressive disease that affects multiple 
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systems of the body including the respiratory, digestive, genitourinary and excretory system.  
With 30,000 Americans currently diagnosed with CF and an annual cost of medical care 
estimated to be about 20,000 dollars per person, or 600 million nationally, it is a serious public 
health concern.  CF, which was first described by Dr. Dorothy H. Andersen in 1938, results from 
mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.  This 
gene was located in 1989 on the long arm of chromosome 7 by positional cloning by Collins, 
Riordan, Tsui and colleagues (2,3).  To date, over 1400 CFTR mutations have been identified, 
but the majority of these do not confer disease status.    
  The CFTR gene codes for the production of CFTR protein which functions as a channel 
to transport ions across cell membranes.  This protein is located in the membranes of cells that 
line the lungs, pancreas, liver, intestines, reproductive tract, as well as the skin.  Mutations in this 
gene result in impaired functioning of these channels, which conduct chloride to facilitate 
movement of chloride out of the epithelial cell to the covering mucus.  This gene also helps 
regulate other ion channels.  Impaired functioning of these ion channels reduces chloride 
transport out of the cell, altering the electrical gradient and contributing to an increase of sodium 
reabsorption.  Without the ability to secrete chloride, and consequent to excess sodium 
reabsorption, the airway surface becomes dehydrated.  In normal airway, regulated movement of 
sodium and chloride maintains an optimal gradient for water to leave the cell and enter the 
extracellular fluid (ECF), however in CF, this lack of salt regulation and the resulting lack of 
water movement causes the mucus lining the ducts and airways to become dehydrated, sticky 
and viscous.  This thickened mucus then aggregates and causes blockages with various 
consequences depending upon the location of the ducts involved.   
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If the blockages are in the ducts of the pancreas, they prevent digestive enzymes from 
leaving the pancreas, resulting in an inability to properly digest and break down food, most 
notably fat.  This is the cause of the malnutrition, poor growth and digestive issues often seen in 
patients with CF.  The lack of pancreatic enzymes is the cause of the bulky, oily, greasy stools 
and excessive gas that are common amongst patients with CF.     
When this blockage occurs in the reproductive tract, it may result in azoospermia, a 
common finding in men with CF.  It should be noted that CF accounts for a significant 
percentage of men with congenital bilateral absence of the vas deferens, a common finding in 
men with CF.  In women, increased cervical mucus has also been noted.   
These duct blockages can also occur in the hepatobiliary tract, causing chronic 
hepatobiliary disease.  An estimated 20-50% of patients express symptoms of hepatobiliary 
disease.  Typically liver involvement presents within the first year of life with increased mucus 
in the bile ducts and ductules.  This may lead to focal biliary fibrosis that is present in about one 
fifth of CF adolescents.  This inflammation and fibrosis is progressive and eventually some of 
these patients, about 5%, develop cirrhosis of the liver [1].   
In the lungs, the increase in mucus viscosity obstructs airflow, contributing to pulmonary 
decline.  It is also responsible for the reduced mucociliary clearance, which when functioning 
properly, clears the airways of debris and particulate matter, as well as bacteria.   Additionally, 
this thickened mucus is sticky and increases the adherence of bacteria, leading to colonization of 
the airways, which is thought to potentially increase the prevalence of respiratory infections [2].  
These recurrent pulmonary infections may result in more inflammation and progressive damage 
to the lungs, causing a cyclic pattern of pulmonary decline.  However it is unclear if the 
inflammation is caused solely by bacterial colonization of the lungs since studies, which will be 
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detailed later, indicate that airway inflammation is present in the lungs of newborns that do not 
have any indication of bacterial infection [3].   
When bacteria enter the lungs and cause an infection, neutrophils (white blood cells) 
attack the infection.  When the neutrophils die, they release DNA and elastase, which continues 
to thicken the mucus.  This further obstructs the airways as well as increases infections and 
inflammation, which will be described in more detail in the Airway Inflammation Section.   
1.1 INCIDENCE/PREVALANCE 
It is estimated that about 30,000 Americans and 70,000 individuals worldwide are living 
with CF.   Each year, approximately 3,200 babies born in the United States will be affected with 
CF. The incidence of CF is about 1 in 2900 in the U.S., making it more common than 
phenylketonuria (PKU) and Galactosemia.  The number of annual deaths attributed to CF is 
roughly 360 deaths each year.  The disease is the second most common life-shortening, 
childhood-onset, inherited condition and has a median age of survival of about 37 years.  
Although CF is panethnic and affects both men and women, the disease-causing mutations are 
more prevalent in Caucasians and individuals of Ashkenazi Jewish descent [4]. The approximate 
carrier frequency of a disease-causing mutation as well as the incidence of CF vary and are based 
upon ethnic background (Table 1). 
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Table 1. CF Carrier Risks and Incidence based upon Ethnic Background [5] 
 
Ethnicity Carrier frequency Incidence1 
Caucasian  ~1/29 ~1/3,300 
Ashkenazi Jewish ~1/29  
Hispanic ~1/46 ~1/8,000-9,000 
Native American  ~1/1,500-3,970 
African American ~1/60-65 ~1/15,300 
Asian American ~1/90 ~1/32,100 
 
1.2 DIAGNOSIS 
The median age at diagnosis for CF is between 6-8 months with the majority of patients 
being diagnosed within the first year of life.  A diagnosis is based upon having at least one 
phenotypic feature characteristic of the disease in addition to one of the following: identification 
of two disease-causing mutations, two abnormal sweat chloride tests, or an abnormal 
transepithelial nasal potential difference (NPD) [6].   
 
                                                
1 Incidence estimations obtained from the Centers for Disease Control and prevention 
http://www.cdc.gov/mmwR/preview/mmwrhtml/rr5313a1.htm 
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Clinical phenotype is variable but the percentage of patients affected with the common 
symptoms can be approximated (Table 2). 
Table 2. Percentage of CF patients affected with common symptoms [5-7] 
 
 Patients 
Affected 
Symptoms 
~50% Acute or persistent respiratory symptoms (includes chronic cough, persistent 
wheezing, and pulmonary infiltrates 
>33% Growth failure 
<33% Obvious symptoms of malabsorption 
~20% Neonatal intestinal obstruction by meconium ileus 
~100% of 
men 
Congenital bilateral absence of the vas deferens 
 
 Additional symptoms include digital clubbing of the fingers and toes, recurrent sinusitis, 
nasal polyposis, electrolyte abnormalities (including dehydration or persistent metabolic 
alkalosis), rectal prolapse, pneumothorax (rupture of lung tissue causing air to be trapped 
between the lungs and the chest wall), coughing up blood, abdominal pain, excessive gas, 
enlarged heart and obstructive jaundice.  Some but not all patients with CF also have diabetes, 
pancreatic inflammation, gallstones or liver disease.  It should also be noted that virtually all 
patients present with chronic respiratory infections[8]. 
1.3 TESTING 
Testing for CF can be conducted in a variety of ways.  Diagnostic testing, carrier testing, 
population screening (newborn screen), pre-implantation genetic diagnosis and prenatal testing 
are all available.  Diagnostic testing may also include chest x-rays, CT scans, lung function tests, 
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an upper GI and small bowel series, pancreatic functioning tests, as well as sputum culture and 
stool examination (fecal fat test, trypsin and chymotrypsin) to assist in confirming a diagnosis.  
The commonly used molecular and biochemical testing is outlined briefly below [9].  
1.3.1 Newborn screen 
The following states have implemented universal newborn screening (NBS) for Cystic 
Fibrosis in the United States: Alaska, Colorado, D.C., Delaware, Georgia, Iowa, Kentucky, 
Maryland, Minnesota, Mississippi, Nebraska, New Hampshire, New Jersey, New Mexico, New 
York, North Dakota, Ohio, Oklahoma, Oregon, Rhode Island, South Carolina, Virginia, 
Washington, Wisconsin and Wyoming.  Massachusetts and South Dakota are universally 
offering NBS for CF but it is not yet required.  Connecticut, Montana and Pennsylvania offer 
NBS for CF to select populations or by request.  Arizona, California, Florida, Michigan, 
Missouri, and Texas are requiring NBS for CF but it has not yet been implemented [10].  The 
Centers for Disease Control and Prevention recommend CF screening for all newborns due to the 
benefits from early diagnosis and treatment.  Babies diagnosed earlier in life can get earlier 
intervention to reduce pulmonary infections and exacerbations as well as better nutrition, 
reduced hospitalizations and improved survival [11]. 
1.3.2 Sweat Test 
The sweat test has long been considered the “gold standard” in diagnosing CF.  It is a 
diagnostic test that quantifies the amount of sodium and chloride in the sweat.  Pilocarpine, a 
colorless, odorless chemical that causes sweating, is applied on the arm or leg.  An electrode is 
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attached to stimulate a weak electrical current to the area.  The sweat from this area is then 
collected on filter paper or in a plastic coil and analyzed.  Increased amounts of salt are 
indicative of CF (normal range is less than 40 millimoles per liter (mmol/L), while a positive 
result is above 60 mmol/L.  A result between 40-60 mmol/L is considered a borderline sweat test 
(Handbook of genetic counseling).  High levels on a sweat test generally indicate cystic fibrosis, 
however they can also indicate adrenal insufficiency, Addison’s disease, hypothyroidism and 
kidney failure [12-14].     
Sometimes, babies don’t produce enough sweat to perform the sweat test, in which case 
the Immunoreactive Trypsinogen (IRT) test is performed.  IRT is a screening test that is used as 
part of the newborn screen, and identifies pancreatic insufficiency.  IRT is performed by 
immunofluorometric assay on whole blood, and can identify the cationic and anionic forms of 
trypsinogen (neonatal immunoreactive trypsinogen).  In the case of newborn screen, IRT is 
performed within the first few days of life.  The IRT is substantially increased in babies with CF; 
however, the relatively low specificity of this test requires that all abnormal results be followed 
by sweat tests and other more specific diagnostic tests [15].   
 
1.3.3 Nasal Potential Difference 
Nasal Potential Difference is used in patients with borderline sweat tests.  It measures the 
voltage across the epithelial surface in the nasal passageways.  This voltage is an indicator of the 
amount of salt transported across the cell membrane [16].   
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Mutations in the CFTR gene result in abnormal transport of chloride ions across secretory 
epithelial cells.  Normally, these ions use chloride channels to enter the cell and exit the cell via 
the basolateral membrane and apical surface, respectively.  They cross the cell membrane via an 
electrochemical gradient.  The ions follow an electrochemical gradient and the channels are 
regulated by phosphorylation that occurs after an increase in cyclic adenosine monophosphate 
(cAMP).   
Sodium ions are transported from the channel through the apical surface of the cell 
creating a voltage or potential difference (PD).  Knowles et al. first developed technique of using 
NPD to measure the potential difference across the nasal epithelium.  Their work showed that 
patients with CF have increased basal potential difference, exaggerated inhibition with amiloride, 
and perfusion with chloride-free and isoproterenol solutions does not affect the potential 
difference [16, 17].  
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1.3.4 Carrier testing 
Mutation analysis is used to determine carrier status in asymptomatic individuals.  In 
1997, a panel from the National Institutes of Health (NIH) issued a statement recommending all 
couples planning a pregnancy or seeking prenatal care should be offered genetic testing for CF 
[5].  In 2001, the American College of Obstetricians and Gynecologists (ACOG) and The 
American College of Medical Genetics (ACMG) issued similar statements recommending a 25 
mutation panel be offered [18, 19].  More than 10 million people nationwide are carriers of a 
CFTR gene mutation [4, 5, 18].  Detection rates based on carrier testing and for the 87-mutation 
panel vary based upon ethnicity (Table 3). 
Table 3. CF Carrier Detection Rates based upon ethnic background [5] 
 
Ethnicity Carrier detection rate 87 mutation detection rate 
Caucasian (non-Hispanic) 78% 85-90% 
Ashkenazi Jewish 97% 97% 
Hispanic 58% 57-85% 
Native American 4% 81-94% 
African American 75% 60-80% 
Asian American 33% 30-38% 
1.3.5 Mutation Analysis 
Molecular genetic testing is used to detect mutations in the CFTR gene in order to 
establish or confirm a diagnosis, to detect asymptomatic carriers and in prenatal testing of at-risk 
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babies.  There are a few options in mutation panel testing (23, 25, 32, 87, 97) offered by labs 
worldwide that perform clinical testing.  In-house testing in various sites range from 21-32 
mutations.  Genzyme laboratory now offers a sequencing test that quotes detection of about 98% 
of 1,200+ disease-causing mutations identified.  Ambry Genetics offers a sequencing that is 
promoted to detect over 99% of 1,500+ known mutations in patients of all ethnic backgrounds.  
Mutation detection rates vary based upon ethnicity as previously described.  Molecular genetic 
testing is performed on whole blood in a yellow-top ACD-A or lavender-top EDTA tube.  For 
adults, 20cc are drawn and for children 5-7 cc are drawn.  Testing can also be performed using 
buccal swabs, which involves obtaining samples from two cheek brushes (one from each cheek).  
Prenatal analysis is performed on 10 cc of amniotic fluid in a 15 ml orange screw-top 
polyprophylene tube or 10-15 mg of chorionic villi in screw-top tubes with transport medium 
[12, 19, 20].   
      Prenatal testing is available and offered in cases where there is a 25% chance of having a 
child with CF based upon family history or previous mutation analysis.  Prenatal tests can be 
performed on either amniotic fluid or chorionic villi samples.  Pre-implantation genetic diagnosis 
is also available for couples interested in pursuing assisted reproduction via in vitro fertilization 
[9]. 
1.4 GENETICS/INHERITANCE 
CF is inherited in an autosomal recessive pattern.  Autosomal refers to the disease-
causing genes residing on autosomes, or the first 22 pairs of chromosomes that do not designate 
sex.  Both men and women share these chromosomes equally, which is consistent with the 
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incidence of disease in both sexes.  Recessive refers to a condition that requires two mutations to 
be present in order to confer disease status.  This means that in order for a child to have CF, both 
parents would need to carry a CF-causing mutation and both would have to pass on that mutation 
to the child (Figure 1).  This would result in the child having two mutated copies of the CFTR-
gene.  Individuals with only one mutation are called carriers and are typically asymptomatic.  
These individuals do not have the disease CF, but are at a fifty percent risk of passing on their 
mutation to each of their children [6]. 
 
 
Figure 1. Autosomal Recessive Inheritance[21] 
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Cystic Fibrosis is caused by mutations in the CFTR gene, which is responsible for coding 
a membrane protein (glycoprotein) that is 1,480 amino acids long and is a chloride channel of 
epithelial cells[22].  The gene is located on the long arm (q) of chromosome 7 and is 230-
kilobases long, includes 27 exons, and produces a 6 Kilobase mRNA product[23]. (Figure 2)   
 
Figure 2. Chromosome 7 location of the CFTR gene[24] 
 
At this time, over 1400 mutations have been identified in the CFTR gene, however the 
vast majority do not predict disease severity.  Most of these mutations are point mutations or 
small deletions that are smaller than 84 base pairs.  The most common disease-causing mutation 
is the delta F508 mutation [23].  This deletion is depicted in figure 3, showing that phenylalanine 
is deleted.  It is interesting to note that although the last nucleotide for the second Isoleucine is 
deleted (the C from ATC), that ATT also codes for Isoleucine (Figure 3).       
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Figure 3. Delta F508 mutation in the CFTR gene[25] 
 
The CFTR gene is an ABC transporter-class protein.  It is comprised of five different 
domains.  There first two are called membrane-spanning domain 1 (MSD1) and membrane-
spanning domain 2 (MSD2), also called transmembrane regions.  These two domains each have 
six spans of alpha helices and are responsible for the chloride ion channel.  They are connected 
to the second pair of domains are called the nucleotide-binding domain 1 (NBD1) and 
nucleotide-binding domain 2 (NBD2).  These two cytoplasmic nucleotide-binding domains bind 
adenosine triphosphate (ATP).  The delta F508 mutation occurs in the sequence of DNA that 
codes for NBD1.  The nucleotide binding folds (NBF) are attached to the fifth domain, which is 
a regulatory (R) domain.  This R domain is unique because most ABC proteins only have four 
domains, while CFTR is the only transporter to contain this fifth, regulatory domain.  It is this 
fifth domain that controls the influx of chloride across the epithelial membrane.  This is 
controlled by the phosphorylation (addition or removal of phosphates).   
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Figure 4. Five domains of the CFTR membrane protein[25] 
There are four classes of CFTR mutations. (Table 3)   
Table 4. Four Classes of CFTR Mutations  
Class of Mutation Type of mutation Examples 
Class 1 mutation: defective 
production 
Results in a premature 
termination of the CFTR mRNA 
translation in the nucleus-
resulting in a significant 
reduction or absence of CFTR 
protein production 
R542X 
Class 2 mutation: defective 
processing 
Results in the degradation of the 
protein within the endoplasmic 
reticulum, resulting in very little 
or no functional protein being 
transferred into the cell 
membrane 
Delta F508 (associated with 
exocrine pancreatic 
insufficiency) 
Class 3 mutation: defective 
regulation 
The protein is located in the 
correct place in the cell 
membrane but it does not 
respond normally to the 
regulatory signals 
R117H (strongly associated 
with pancreatic sufficiency) 
Class 4 mutations: defective 
conduction 
 
The protein is located in the 
correct place in the cell 
membrane but the transport 
properties do not function 
properly.  
R347P 
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1.4.1 Genotype/Phenotype correlation: 
Pancreatic sufficiency is the best example of genotype/phenotype correlation in patients 
with CF. Some mutations are classified as pancreatic-sufficient (PS) or pancreatic-insufficient 
(PI).  In general, patients with pancreatic sufficiency have a milder clinical course as well as an 
increased median survival rate.  These patients have a median survival of about 56 years, 
however they only make up about ten percent of the CF population.  While no distinct genotype-
phenotype correlations have been made in regards to pulmonary function and disease, research is 
still being conducted to investigate potential correlations.  One study conducted by deGracia et 
al. identified an association between more severe respiratory disease and lower survival and 
having a class I or II mutation on both genes [26].  Another conducted in Europe identified an 
association between the G85E mutation and a severe phenotype [27].        
1.5 BRIEF REVIEW OF MANAGEMENT 
Discussing the management of a multi-system disease with a lot of phenotypic variability 
in terms of disease severity and symptoms cannot possibly be comprehensively covered in the 
scope of this paper, however some of the major management strategies and procedures will be 
briefly discussed.  Issues regarding pulmonary function tests will be discussed in the following 
section entitled Pulmonary Function.   
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1.5.1 Airway clearance  
Airway clearance is one of the most critical components in maintaining the health of the 
lungs and slowing the progression of lung disease.  Airway clearance can be performed through a 
variety of methods including manual chest therapy (percussion), physical therapy including 
aerobic exercises to help loosen mucus, and gravity drainage that is conducive to moving 
secretions from the lower airways (postural drainage), mechanical vests to vibrate the chest, and 
hand-held breathing devices (flutter) [28].   
1.5.2 Nutrition 
Most patients with CF hav pancreatic insufficiency and rely on the daily use of pancreatic 
enzyme supplements at every meal to aid in food digestion.  Since malnutrition is a major 
problem with this disease, pancreatic enzyme replacement and fat-soluble vitamin supplements 
(ADEK) are essential.  These patients follow a high-calorie diet due to the malabsorption (even 
with pancreatic enzymes).  Many patients struggle with weight-gain or maintenance.  Women 
with CF will sometimes also have complications with irregular menstrual cycles due to 
malnutrition and weight-loss [6, 28].  
Monitoring of growth by plotting height and weight in children and weight in adults as 
well as annual screening labs for vitamin A and E levels helps ensure patients are maintaining 
their weight and vitamin levels.  Diabetes screening is performed and BMI is followed in adults; 
another indicator of nutritional status is skin fold thickness, obtained through the use of 
anthropometric skin fold calipers.  Generally, ketoacidosis is rare, however, decreased glucagons 
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release increases the risk for hypoglycemia.  Some patients require gastrostomy feeding (g-tube) 
to meet their nutritional needs and maintain or gain weight [6, 28].   
1.5.3 Medications (inhaled aerosols, salines, steroids) 
Antibiotics, corticosteroids, inhaled bronchodilators such as albuterol (Proventil, 
Ventolin) are used to help open the airways.  DNAse enzyme replacement therapy helps thin 
mucus secretions and preserve lung function [29].  Over the counter anti-inflammatory 
medications are thought to help slow disease progression.  Anti-inflammatory medications will 
be further described in section 2.2 “Treatment For Airway Inflammation.”  
1.5.4 Transplantation for CF:  
Approximately 3% of patients with CF have severe liver disease caused by hepatobiliary 
duct blockages that ultimately results in cirrhosis.  About one fourth of patients have focal areas 
of cirrhosis.  These transplants are generally viewed as a last resort for patients.  Additionally 
heart-lung and bilateral lung transplants are also performed on patients with end-stage lung 
disease, and are again viewed as a last resort.  While individual results may vary greatly in 
prognosis and outcome, the median survival of transplant patients is currently estimated to be 
about 5 years for lung transplant recipients, and longer for liver recipients [28].     
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1.6 PROGNOSIS 
The overall prognosis for patients with CF is highly variable and depends on the severity 
and extent of their disease.  The median survival in 2005 was estimated to be about 37 years of 
age, with pulmonary disease being the major cause of morbidity and mortality [6].  Individuals 
with less severe disease can live significantly longer.  
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2.0  PULMONARY FUNCTION  
Cystic Fibrosis affects numerous organs and systems, including the gastro-intestinal tract, 
liver and reproductive system (vas deferens-obstructive azoospermia, cervical mucus, etc), 
however, the primary scope of this paper will be focused upon the pulmonary system and airway 
inflammation.  Although CF is not associated with immune deficiency, as previously discussed, 
mutations in CFTR result in changes in ion transport.  These changes lead to the increased 
susceptibility of the lungs to endobronchial infections.  Endobronchial infections are usually 
caused by bacteria such as Pseudomonas aeruginoas.  The airway inflammatory response also 
ultimately leads to progressive lung damage.  Pulmonary function is affected by several things 
including, recurrent respiratory infection, bacterial colonization, airway inflammation and 
oxidative stress, all of which contribute to the progressive pulmonary disease in CF [30-32] 
Assessing pulmonary function can be performed by measuring oxygen saturation (SaO2), 
lung volumes such as functional residual capacity (FRC), mixing index (MI), total respiratory 
system compliance (Crs), and maximal flow at FRC (VmaxFRC).  The most common method of 
measuring pulmonary function is a test called Spirometry [33, 34].   
Oxygen saturation has been studied to determine its usefulness as a non-invasive marker 
to assess patient progress.  In one study by Betancourt et al., in 1991, the median SaO2 in 50 
patients with cystic fibrosis was 94.0%, which was significantly lower than the median SaO2 that 
that of the 50 controls (patients with stable asthma), which measured 97.0% [33].  A study by 
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Chetta et al., in the 2001 Respiratory Medicine showed that adults with mild or moderate 
pulmonary disease showed no significant difference in the 6-minute walk distance but 
experienced a significant decrease in oxygen saturation as well as perceived dyspnea [35]. 
Spirometry is considered one of the most important ways to monitor pulmonary status 
and is used to measure the amount and speed of airflow into and out of the lungs.  It is often used 
to monitor pulmonary conditions such as CF, asthma and Chronic Obstructive Pulmonary 
Disease (COPD).  The volume and flow rates of air that a patient is able to produce are measured 
by the raised-volume, rapid thoracoabdominal compression technique.  The test is performed on 
a machine called a spirometer, while the nose is pinched closed with nose clips.  Spirometry 
measures slow vital capacity (SVC), forced vital capacity (FVC), forced expiratory volume 
(FEV), forced expiratory flow (FEF) and Maximal voluntary ventilation (MVV).  Functional 
residual capacity (FRC) can be measured by a plethysmograph [36, Schluchter, 2006 #67, 37].     
Tidal volume refers to the amount of air that is expelled during normal exhalations.  This 
measurement is obtained when the patient is breathing normally.  Typically this number reflects 
much less than eighty percent of the lungs total capacity, which is sometimes referred to as Total 
Lung Capacity (TLC).  The residual volume (RV) refers to the amount of air that remains in the 
lungs after a full exhalation.  Forced vital capacity measures the amount of air exhaled after 
inhaling as much as possible.  It is obtained by taking a measurement of the patient breathing in 
fully and exhaling as quickly and forcefully as possible [36, 38, Vilozni, 2007 #31, Nixon, 2002 
#5, 39].   
Forced expiratory volume (FEV) measures the amount of air exhaled in timed intervals.  
FEV-1 is the amount of air exhaled in one second and is the most frequently used FEV 
measurement.  Forced expiratory flow (25-75%) averages the flow between 25 and 75% of vital 
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capacity.  In other words, the FEF25-75 is the rate of air flow in liters exhaled per second 
between these two time intervals and is a good indicator of the condition of the medium and 
small sized airways. [36, 38, Nixon, 2002 #5, Vilozni, 2007 #31, 39] 
Maximal voluntary ventilation (MVV) measures the volume of ventilation while the 
patient is breathing as quickly and forcefully as possible for 15 seconds.  This test is used to 
monitor the respiratory strength and stamina [34].  These measurements are then specified in 
liters as well as percent predicted.  The latter is the percent of the predicted values for patients of 
the same growth (height and weight), sex, age and occasionally race.  Percentages ranging from 
around 80-100% are generally considered within the normal range, and the level of impairment 
is classified based upon % predicted, however this varies from physician to physician and based 
upon individual circumstances and health issues.  The general level of impairment corresponds  
to the percent predicted of FVC and FEV1 [35]. (Table 5)  
 
Table 5. Pulmonary Function and Impairment Classification  
 Mild  Moderate Severe 
FVC % pred 60-79 40-59 40 or less 
FEV1 % pred 60-79 40-59 40 or less 
FEV1/FVC % pred 60-69 40-59 40 or less 
 
 
Spirometry does have limitations however, that include requiring the full and active 
participation of the patient.  Additionally, it is only accurate on patients that are old enough to 
follow instructions, meaning that young children are typically excluded.  Additionally, patients 
that are sedated, unconscious or are unable to exert the energy to perform the test cannot be 
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monitored.  The recommendations for the frequency of conducting pulmonary tests are set based 
upon age.  (Table 6).  These tests may be repeated after administration of a bronchodilator such 
as Albuterol, and is called a reversibility test or post bronchodilation test (post BD) [36] [40].  
 
 Table 6. Pulmonary test/frequency based upon age[34]  
Age Pulmonary test/frequency 
0-3 Infant pulmonary function test 
3-5 Spirometry based upon ability 
6-7 Spirometry each visit 
8+ Spirometry each visit, lung volumes as needed 
 
 
Serum, sputum and other markers can be used to measure airway inflammation, and the 
literature indicates that exhaled gas measurements may provide a non-invasive way to determine 
early indications of airway inflammation, resulting in the possibility of earlier treatment and 
reduction of respiratory infection[41].   
2.1 AIRWAY INFLAMMATION  
Airway inflammation is a significant factor in the development and progression of lung 
disease in patients with Cystic Fibrosis.  The increased susceptibility of the lungs to 
endobronchial infections may occur via several possible mechanisms.  The first is that mutation 
in the CFTR gene causes altered chloride secretion and increased sodium re-absorption, altering 
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the amount of water in the airway secretions resulting in dehydration.  This dehydration causes 
the mucus to become viscous and sticky and also prevents cilia from functioning properly to 
clear mucus [42].  The outcome of altered mucus clearance is recurrent bacterial infections and 
airway inflammation.   
A second mechanism suggests defects in the host defense.  The airways are lined with 
what is called airway surface liquid (ASL).  This thin fluid layer has antibacterial properties, 
which functions to prevent inhaled bacteria from causing infections.  Studies have indicated that 
the airway surface liquid in CF patients does not have the antibacterial properties, which are 
normally present in the ASL.  This lack of antibacterial properties is attributed to the increased 
salt content in the ASL [39, 43].  Further investigation suggested that the antibacterial factors 
present in ASL were lysozyme and lactoferrin.  More recent studies have failed to confirm this 
mechanism, and the prevailing consensus is that depletion of airway liquid volume, rather than 
altered salt composition, is the major cause of infection in CF. 
A third mechanism suggests that mutations in CFTR are associated with increased 
Pseudomonas and Staphylococcus aureus adherence in the airway epithelium.  Pseudomonas 
aeruginosa produces large quantities of alginate (a polysaccharide matrix), which adheres to the 
damaged epithelial cell surfaces of the airway.  This adherence makes it very difficult for the 
lungs to clear the organisms after an infection [44, 45].  Inability to effectively clear the lungs 
results in chronic inflammation and continued damage to the epithelial cell surface [46] .   
Fourth is the characterization of CFTR as a key membrane receptor, which acts in 
binding and killing P. aeruginosa, which is compromised in patients with CF.   
The literature indicates that patients with CF are born with healthy lungs and that 
endobronchial colonization of organisms including Staphylococcus aureus, Haemophilus 
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influenzae, Klebsiella pneumoniae and Escherichia coli does not occur until after birth.  The fact 
that these patients are born with healthy lungs indicates that a “first line of defense” against 
infection, called the “innate immune system,” is compromised in CF [40, 47].   
The inflammatory process involves continuous assault on the airways by neutrophils.  
Neutrophils release substances including reactive oxygen species (destructive oxidases) and 
proteolytic enzymes (proteases).  Both of these noxious mediators cause damage the lungs, with 
the elastase degrading the structural proteins.        
The innate defense system includes “alveolar macrophages, neutrophils and epithelial 
cells”.  “Neutrophils” are white blood cells that are filled with granules (tiny sacs of enzymes) 
that aid in killing and digesting microorganisms the cell has engulfed via phagocytosis [47].    
Mucociliary clearance is the mechanism by which pathogenic particles are cleared.  The 
first step in this process occurs when mucus functions to trap particles, which can then be moved 
by cilia.  The cilia along with help from aerodynamic filtering and airway reflexes (such as 
coughing and sneezing) aid in clearing these particles from the lungs [47].  
There are several methods employed for measuring airway inflammation.  
Bronchoalveolar lavage (BAL) is used in some centers routinely, however, it is an invasive 
procedure.   High-resolution CT may also be used, however because it uses radiation, its use 
must be limited and this technique has not been validated for routine monitoring of airway 
inflammation[48].  Various methods currently being used to examine airway inflammation and 
infection will be discussed.   
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2.2 TREATING AIRWAY INFLAMMATION 
Airway inflammation is often treated using corticosteroids, macrolides, or non-steroidal 
anti-inflammatory drugs (NSAID), and further research investigating the safety and efficacy of 
leukotriene antagonists is also being conducted [49].      
2.2.1 Corticosteroids (Prednisone) 
Corticosteroids are widely known for their anti-inflammatory properties and are 
commonly used for patients with Cystic Fibrosis in order to treat allergic bronchopulmonary 
aspergillosis (ABPA), steroid-responsive wheezing, refractory airflow obstruction and to reduce 
the local inflammatory response.  Corticosteroids are thought to work either by inhibiting the 
production of neutrophils or inhibiting the migration of neutrophils by releasing chemotaxins like 
IL-8.  Auerbach et al, conducted a study over four years and found that patients treated with 
corticosteroids had fewer respiratory infective exacerbations, lower IgG levels and better 
nutrition.  Other studies following this research revealed side effects from treatment including 
diabetes and growth suppression [7].  Treated patients with chronic P. aeruginosa infection upon 
entry of the study had better respiratory function as measured by FVC. Growth suppression 
appeared to be irreversible, especially if treatment begins in males before adolescence [50].  
Another study by Greally et al. indicated treated patients had an increase in respiratory function 
and reduction in IgG and cytokines [51].  Additional side effects include adrenal 
suppression/insufficiency and osteoporosis [52].          
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2.2.2 NSAIDS (Ibuprofen) 
Non-steroidal anti-inflammatory drugs act as inhibitors to neutrophil migration, 
adherence and lysosomal enzymes when taken in high doses.  Studies have indicated that this 
treatment can lessen the progression of lung disease, as well as weight and chest radiographic 
scores.  Since this improvement was really only seen in patients who were under the age of 13, it 
is thought that the timing of treatment is critical and that children between the ages of 5-12 
would benefit the most.  Side effects include toxicity and plasma levels need to be carefully 
regulated[48].  
2.2.3 Macrolides (Erythromycin, Clarithromycin and Azithromycin) 
Macrolides are antibiotics commonly used to treat Mycoplasma pneumonia, Chlamydia 
pneumonia and legionella, however recently they have been suggested to act as an anti-
inflammatory for patients with CF as well as reduce sputum viscosity and airway adhesion of P. 
aeruginosa[28].                
2.2.4 Defensins and cathelicidins   
Defensins and cathelicidins are peptides produced in airway epithelial cells, macrophages 
and neutrophils and found in higher quantities in the airway surface liquid of patients with 
CF[53].  It has been suggested that the increase in sodium in the airway surface fluids of patients 
with CF results in the reduced ability to kill bacteria[54].   
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2.2.5 Leukotriene receptor antagonists 
Leukotrienes are released as part of the inflammatory response and are found in high 
quantities in the sputum of patients with CF.  In patients with CF, inhibiting leukotrienes has 
been associated with a reduced need for antibiotics, fewer inflammatory markers, less dyspnea as 
well as overall improved well-being and a reduction in eosinophilic inflammation, in one small 
study [55], however further research needs to be conducted to support this therapy.          
2.2.6 Alpha-1 antitrypsin and secretory leukoprotease inhibitor (SLPI) 
Airway cells produce Alpha-1-antitrypsin (a-1AT) and Secretory Leukoprotease Inhibitor 
(SLPI), two antiproteases that function to protect the lungs from damage caused by Elastase 
enzyme.  Research involving the use of aerosol-administered supplemental antiproteases is 
underway, and needs to be conducted in order to establish the safety and efficacy of this 
treatment[28]. 
2.3 MARKERS FOR AIRWAY INFLAMMATION 
The most commonly used markers for airway inflammation include serum C-reactive 
protein (CRP), serum immunoglobin (immunoglobulin G), and blood neutrophil cell count[46]. 
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2.3.1.1 Sputum  
Increased concentrations of pro-inflammatory cytokines including IL-1, tumour necrosis 
factor-alpha, and IL-6, have been detected in CF sputum and are known to increase airway 
inflammation.  Sputum can also be obtained to measure the increased amounts of 
deoxyribonucleic acid (DNA) that accumulates when neutrophils decompose, indicating 
pulmonary exacerbations.    High levels of active collagenase (a neutrophil protease) have been 
reported in CF sputum and are most likely inversely related to the severity of the disease.  
Increased amounts of oxidants (chloramines, taurine and myeloperoxidase) and chemoattractants 
(LTB4 and pro-inflammatory cytokines) have also been increased in CF sputum.  Cytokines are 
chemical signals made up of proteins and peptides and used by cells to communicate with each 
other.  They play a central role in regulating innate immune responses and are involved in 
inflammatory diseases [51, 56-58]. 
Although induced sputum is used to help assess the presence of inflammation, it requires 
the use of inhaled hypertonic saline, which can cause coughing and bronchoconstriction.  For this 
reason it is considered minimally invasive.  It is also challenging to obtain sputum on younger 
children.  Additionally, this procedure is limited by the fact that it causes an inflammatory 
response, which can’t be repeated within a 24-hour time period [41, 48].   
2.3.2 Serum/Plasma and Urine 
Serum is used to measure C-reactive protein and antioxidant levels, which may indicate 
inflammation (oxidative stress) [46, 59].  Additionally, lipid peroxide levels are also studied 
because severe lung disease in CF has been associated with increased levels of lipid peroxides.   
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Biomarkers like eosinophil granule proteins (EGP) are measured in the blood and urine 
of patients with CF, and other lung diseases.  Increased serum ECP as well as EGPs suggests 
eosinophil participation in any chronic inflammatory process, however, these eosinophil markers 
in peripheral blood do not seem to be disease-specific.  Serum ECP levels correlate with ECP 
levels in BAL fluid from patients with asthma and ECP concentrations in the sputum of patients 
with cystic fibrosis.  This finding suggests that eosinophil activity in the blood correlates to 
eosinophilic inflammation in the lungs [46, 48].  
Peripheral blood may also used to measure the level of myeloperoxidase (MPO), 
lactoferrin and human neutrophil lipocalin (HNL), which are proteins that are produced by 
neutrophils.  The levels of MPO in the serum have correlated with levels in sputum, indicating 
that serum levels reflect inflammation levels in patients with CF.  HNL proteins appear to be 
able to differentiate between chronic and acute infections in CF much more accurately than MPO 
and lactoferrin.  This is advantageous in that serum markers for neutrophil activity are easier to 
process than serum for EGPs.  This measurement is limited in that bacterial infections in other 
parts of the body can also increase the levels of these serum proteins, meaning that raised levels 
do not necessarily indicate that the infection is confined to or involving the airways [58]. 
Peripheral blood can be used to measure cytokines and adhesion molecules in order to 
monitor airway inflammation, however interpreting the levels is difficult.  Peripheral blood is 
also used to monitor interleukin 1, 4, 5, 6 and 8 as well as interferon, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), and tumor necrosis factor  (TNF)[58]. 
Urine is used to study oxidative stress by looking at urine TNF receptor 1.  The Oxidative 
Stress Analysis detects urinary salicylates, which are markers of hydroxyl radical activity.  Urine 
lipid peroxides, glutathionine peroxidase, superoxide dismutase and reduced glutathione are also 
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measured to help identify potential sources of cellular damage that may exacerbate the 
disease[41, 46, 58]. 
Glutatione is the major antioxidant in the lungs, and has been found to be decreased in 
the epithelial lining fluid of the lungs and in the plasma of patients with CF. This is thought to be 
due to the CFTR mutation.  This becomes problematic when recurrent infections lead to the 
influx of activated neutrophils, which release free radicals.  As a result of the decrease in 
glutathione, the other antioxidants that are present are not capable of counteracting this increased 
amount of free radicals that have been produced [31].  
2.3.3 Bronchoalveolar lavage fluid (BALF) 
Increased concentrations of pro-inflammatory cytokines (IL-1, tumour necrosis factor-
alpha, and IL-6) have been detected in the BALF of CF patients and are also associated with 
airway inflammation.  The number of neutrophils in the BALF is also an indicator of the 
inflammatory process[60].  Increased levels of IL-8 and neutrophils have been found in the 
BALF of newborns with no other signs or symptoms of infection, suggesting that inflammation 
is present before infection[61].  IL-8 is produced by macrophages and endothelial cells and target 
neutrophils, and is important for white cell migration (chemotaxis).  In one study comparing the 
cytokine response in airway epithelial cells, the CF phenotypic line had significantly more IL-8, 
IL-6 and granulocyte-macrophage colony-stimulating factor[3]. 
Bronchoalveolar lavage fluid is obtained by performing a bronchoalveolar lavage, which 
is a medical procedure that involves inserting a bronchoscope into the lungs through the mouth 
or nose.  Fluid is instilled into a small part of the lung and then collected for examination.  This 
procedure is typically performed in order to diagnose lung disease, or to identify infection.  One 
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of the main limitations in using bronchoalveolar lavage is the wide range of normal values for 
each parameter, which makes this sample insensitive in detecting disease.  Additionally, 
abnormal results are not disease-specific, making interpretation difficult.  Some individuals will 
have abnormal BALF results and not have any indication of disease, while others with known 
disease have normal BALF results.  Additionally, the process of removing BALF may damage 
some of the cells and change the fluid from the epithelial lining [46, 48]. 
2.3.4 Exhaled Gas 
Exhaled Gas is used as a non-invasive way to measure the amount of both end-tidal and 
sometimes mixed expired gas in the lungs.  Levels of various exhaled gas mediators have been 
correlated with different pulmonary conditions.  This measurement will be discussed in the 
section entitled Exhaled Gas Markers[62] [63].  (Table 7) 
 
 Table 7. Profile of different exhaled gas mediators[64, 65]  
 NO CO 8-isoprostane 
Asthma Large increase Modest increase Moderate increase 
COPD Little/no increase Large increase Large increase 
Cystic Fibrosis Decrease Large increase  Large increase 
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2.3.5 Other biochemical markers 
Although the focus of this project is to explore the use of exhaled gas measurements as 
markers for inflammation in the airways of patients with CF, it is important to acknowledge 
other non-invasive measurements for inflammation as well as additional uses of exhaled breath.  
Exhaled breath condensate is also being studied extensively as a potential marker for 
inflammation.  This is another completely noninvasive marker for inflammation that uses 
exhaled air and cools or freezes it for condensation.  It does not affect airway function or induce 
an inflammatory response, so it can be repeated without limitation.  Non-volatile substances like 
proteins and pulmonary surfactants as well as inflammatory markers like oxidants and ions have 
been collected and measured from breath condensate.  The basic idea behind breath condensate 
is that airway surface liquid becomes aerosolized and that the condensate collected reflects the 
composition of the airway surface liquid [65].  Additionally, exhaled breath condensate enables 
us to look at the eicosanoid profile in patients.  This is advantageous because eicosanoids are 
inflammatory mediators and are thought to control vasodilation, vasoconstrction, plasma 
exudation, mucus secretion, bronchoconstriction, bronchodilation, cough and inflammatory cell 
recruitment [64].   
Exhaled breath analysis can also be used to detect levels of volatile hydrocarbons.  The 
primary source of these exhaled hydrocarbons is the liver, and they are excreted in the breath and 
used to monitor lipid peroxidation. Additional volatile gases including ethane and pentane are 
also studied.  Exhaled ethane has been found to be elevated in correlation with the exhaled CO 
and airway obstruction found in patients with CF.  These findings indicate that oxidative stress 
and lipid peroxidation are both increased in patients with CF.  Measurements of hydrogen 
peroxide have been significantly lower in patients with exacerbations of CF (including bacterial 
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infection) when treated with antibiotics [65, 66].  Although these exemplify the various uses of 
exhaled gas, the use of these measurements are really beyond the scope of this project and will 
not be further elaborated upon.   
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3.0  EXHALED GAS MARKERS 
Exhaled gas as a marker for airway inflammation is useful in that it is non-invasive, 
relative easy to obtain and can measure several different exhaled gases, including carbon 
monoxide, carbon dioxide and nitrogen oxide.  Exhaled gas measurements are often used in 
various arenas not limited to pulmonary disease.  End tidal exhaled gas measurements are often 
used as standards of care because they are safe to perform.  The Intensive Care Society requires 
end tidal carbon dioxide monitoring for all patients being transported[67].  Additionally, the 
American Heart Association recommends that all patients undergoing intubation are confirmed 
with an end tidal carbon dioxide measurement[68].  End-Tidal Carbon Monoxide (ETCO) is 
commonly used to help assess and diagnose children with haemolytic diseases [69].  Exhaled CO 
has also been used to monitor cardiovascular disease, diabetes, nephritis, bilirubin production, 
lung diffusion capacity as well as to help identify current and passive smokers, further 
illustrating its varied use in the medical field.   
3.1 CARBON MONOXIDE 
Exhaled Carbon Monoxide (CO) has different sources, including that produced through 
enzyme-induced heme catabolism, non-heme-related release of CO and exogenous CO.  Non-
heme-related release of CO includes what is released through lipid peroxidation, and from 
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xenobiotics and bacteria.  The vast majority of endogenous CO is produced when heme is 
catabolized by the enzyme heme oxygenase-1 (HO-1), and also results in the production of the 
antioxidant bilirubin, the induction of ferritin and the removal of iron [31].  HO-1 can be up 
regulated by cytokines and oxidants during the inflammatory response in the lungs.  This up-
regulation has a protective effect against oxidative stressors, and is thought to increase the 
amount of exhaled CO.  It is estimated that about eighty percent of the CO that is produced from 
heme catabolism is exhaled [65].     
Elevated CO levels are seen in individuals with inflammatory conditions such as upper 
respiratory infections, asthma and bronchiectasis.  These findings suggest that there is more 
oxidative stress in these conditions.  Some studies indicate that CF patients have elevated CO 
levels that would also indicate oxidative damage.  Thus we would expect to see markers of this 
oxidative damaged increased during exacerbations of CF [59].  
Alveoli are thought to be the primary source of exhaled CO because the amount of CO is 
not affected by airflow.  Additionally, the amount of CO at the very end of an exhalation is 
approximately that measured by a bronchoscope.  The level of exhaled CO peaks at the end of 
the breath and is typically measured by using electrochemical sensors, although laser 
spectrophotometers and near-infrared CO analyzers are also used[31].     
In asthma, and perhaps in other pulmonary diseases that are associated with chronic 
airway inflammation, the amount of inducible nitric oxide synthase (iNOS) producing nitric 
oxide (NO) and inducible heme oxygenase (HO-1) releasing carbon monoxide (CO) correlates 
with other markers of airway inflammation.  Concentrations of exhaled NO and exhaled CO are 
also higher in patients with bronchiectasis, which may reflect the iNOS and HO-1 expression in 
macrophages and neutrophils in the airways of these patients [70].  In one study conducted by 
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Horvath et al, the levels of exhaled and nasal NO and CO in patients were compared.  The 
amount of exhaled NO in patients with primary ciliary dysinesia (PCD) and CF was found to be 
significantly lower than the levels found in healthy subjects [70].     
As previously mentioned, End-Tidal Carbon Monoxide (ETCO) is produced through the 
catabolism of heme and then diffused to the air in the alveoli.  This is important because the 
diffusion capacity of CO (DLCO) or the surface area of the alveoli may affect the amount of CO 
that is transferred from the blood stream to the alveoli.  Decreases in lung volume and DLCO 
may occur in patients with CF, affecting the ambient ETCO.  Ambient ETCO may be affected by 
other conditions, which could increase the rate of heme catabolism.  These conditions include 
anemia, hematomas and fasting [71].   
One of the major advantages of using CO measurements from exhaled gas is that the 
quantity of CO is much higher in exhaled air amounts than NO, which is also used as a marker 
for inflammation.  While NO is measured in parts per billion, CO can be measured in parts per 
million.  This is financially advantageous, as the equipment required to measure CO is less 
expensive than the equipment needed to measure exhaled NO [72].  Often times the equipment 
used to measure CO relies on electrochemical sensors, which are inexpensive but sensitive to the 
influence of other gases like hydrogen [62].   
Limitations of CO measurements are possible confounders including exposure to 
cigarette smoke (first or second-hand), car exhaust and various other pollutants, which can 
increase the amount of exhaled CO [72].  Additionally, the amount of ambient air that is inhaled 
by the patient is also a potential confounder so correcting for inhaled air is necessary for accurate 
measurements.    
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Studies have been conducted that have shown an increase in the End-Tidal carbon 
monoxide in patients with CF, however since conflicting data indicating no increase in CO has 
also emerged, some of the studies will be discussed and reviewed[31, 59, 72, 73].    
3.2  NITRIC OXIDE 
Nitric Oxide (NO) is a gaseous chemical compound produced by macrophages, 
neutrophils and stimulated bronchial epithelial cells.  It mediates inflammatory and the immune 
response in the lungs and regulates the smooth muscle contractility in the airways as well as 
pulmonary perfusion.  Higher levels have been found in the exhaled condensate of asthma 
patients, suggesting a possible role in the pathophysiology of airway inflammation.  NO is 
produced along the surface of the airways, which secrete it into the lumen where it mixes with 
the NO from the alveoli [65].  It is also produced more during bacterial infections, therefore we 
would expect to see higher amounts of exhaled NO in patients with recurrent infections and 
inflammation, including CF.  Contrary to reasoning, patients with CF actually have lower 
amounts of NO in their exhaled condensate, which may be due to the increase in mucus 
viscosity.  This increase in viscosity and amount of mucus may keep NO from entering the 
airway or may actually serve to trap and remove NO through oxidative reactions [64].     
Ho et al. suggested that exhaled NO may not be an accurate indicator of the amount of 
NO produced in the airways because of the amount of byproducts found (nitrate and nitrite) and 
that these byproducts from the metabolism of NO may be better indicators of the actual amount 
of NO being produced[64].   
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The increase of NO present in exhaled gas is due to the increased production of inducible 
nitric oxide synthase (iNOS).  This iNOS is located in inflammatory cells and epithelial cells, 
and increases the production of NO.  There is a significant increase in the expression of iNOS in 
the airway epithelium in patients with asthma [72].   
According to Matsui, et al., “Nitric oxide may regulate airway function in the 
pathophysiology of inflammatory airway disease.  Exhaled NO has been shown to be a marker of 
inflammation in asthma and bronchiectasis.  However, despite chronic airway inflammation in 
cystic fibrosis, exhaled NO levels appear to be lower than normal possibly because of a reduced 
expression of the inducible form of NO synthase (iNOS), trapping of NO in the mucous layer, or 
because NO is metabolized to peroxynitrite making this measurement of little use for monitoring 
the lung inflammation in cystic fibrosis”[42].   
Exhaled NO levels may be affected factors like soft palate closure, expiratory flow, and 
dead space air.  Exhaled NO is also no affected by variables like the age, sex and lung function 
of the patient.  It has been suggested that because the hormone estrogen activates endothelial 
NOS (NOS3) in airway epithelial cells, that a woman’s menstrual cycle may alter her exhaled 
NO measurements [65].  While external variables including NO ozone and chlorine dioxide can 
increase exhaled NO levels, factors like alcohol consumption and smoking can decrease exhaled 
NO.  Other factors can also affect exhaled NO like upper respiratory infections, which are known 
to greatly increase the amount of exhaled NO [65].   
Lower NO values are associated with chronic cough that are not caused by asthma.  NO 
is measured using chemiluminescence analyzers.  This type of testing used to be limited due to 
the high cost of the equipment but a number of companies are making machines, and they are 
now used routinely in many asthma clinics[70, 74].    
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3.3 OBTAINING GAS MEASUREMEMNTS 
3.3.1 End Tidal 
End-tidal exhaled gas measurements are obtained during an exhalation and reflect the gas 
level at the very end of the breath.  End tidal (ET) measurements are obtained by tracking the 
flow of the air during the exhalation and then measuring the level of the gas at the end of the 
tidal volume[63].      
3.3.2 Mixed Expired 
Mixed-expired gas measurements are obtained by collecting the gas from the entire 
exhalation into a vacuumed, airtight bag.  The gases have an opportunity to distribute evenly 
(mix) and the measurement is taken from this mixture and averages what was collected during 
the exhalation.   Mixed-expired gas measurements are thought to reflect the gas coming from the 
alveolar dead space and the alveoli of the lungs[34].   
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4.0  PRIOR STUDIES 
4.1 EARLY AIRWAY INFECTION, INFLAMMATION, AND LUNG FUNCTION IN 
CYSTIC FIBROSIS BY NIXON ET AL. 
In this study, conducted by Nixon et alForced Expiratory Volume (FEV) and Bronchial 
Lavage (BAL) were used to assess the role of inflammation and its relationship to lower airway 
infection in infants and children under the age of three, with CF [39].   
Methods:  The study looked at 36 children with CF, all of whom were under the age of 
three.  BAL was used to indicate lower airway infection and was performed right after FEVs, 
which were used to assess lung function. 
Results:  Lower airway infection as evidenced by BAL, was associated with a decrease in 
FEV by 10%.  Twenty of the subjects had a daily moist cough the week prior to testing and 
seven had an infection detected.  Subjects with a daily cough had lower FEVs than those without. 
Conclusions:  It appears that airway infection, as well as respiratory symptoms (such as 
daily coughing) affect lung function, both independently and with an additive effect.  No 
assocationa between airway inflammation and lung function was identified.  
Discussion:  This study was not hypothesis-driven but was designed to help determine the 
relationship between lower airway infection and inflammation, respiratory symptoms and lung 
function.  A larger sample size, especially including more subjects that were without moist cough 
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prior to testing would be helpful in establishing the relationship between respiratory symptoms 
and lung function.  This study was limited in that it only looked at seven patients with infection, 
so establishing a relationship between infection and pulmonary function requires more data.      
4.2 EXHALED CARBON MONOXIDE IS NOT ELEVATED IN PATIENTS WITH 
ASTHMA OR CYSTIC FIBROSIS BY ZETTERQUIST ET AL. 
Zetterquist et al., conducted a study entitled “Exhaled carbon monoxide is not elevated in 
patients with asthma or cystic fibrosis” in which the researchers looked at whether or not Carbon 
Monoxide measurements from exhaled air can be used as a marker of inflammation.  The theory 
is based upon increased CO production in inflammatory states could be due to the induction of 
Heme oxygenase (HO-1) which would be an indicator of oxidative stress.  However studies have 
not clearly supported the increase in HO-1 in disorders involving airway inflammation[72].     
Methods:  32 asthmatic patients without steroid treatment, 24 steroid-treated asthmatics 
(16 with allergic rhinitis and 9 with CF) were compared to 30 healthy controls (non-smokers).  
End-tidal CO and NO measurements were taken.  Two CO machines were used, the first was a 
fast-response, nondisperse infrared (NDIR) CO analyzer and the second was an electrochemical 
sensor.  The researchers opted to measure CO and NO after a breath-hold in order to help 
determine if the molecule originally came from the alveoli or the bronchi.  This is distinguished 
because end-tidal CO or NO from the alveoli should increase after a breath hold whereas end-
tidal CO or NO from the bronchi should remain the same after a breath hold. 
Results:  No increase in the level of CO among patients with allergic rhinitis, steroid-
naïve asthma, steroid-treated asthma, or CF.  Levels of NO were significantly elevated for pts 
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with allergic rhinitis and steroid-naïve asthma when compared to controls.  Steroid-treated 
asthma patients did not have a significant increase in NO.  Patients with CF showed lower 
concentrations of NO when compared with controls. 
Conclusions: The results from both of the CO analyzers used showed no significant 
increase in fractional concentration of exhaled CO in patients with airway inflammation 
disorders including CF, asthma and allergic rhinitis, when compared to healthy controls.  A 
decrease in the NO levels of patients with CF was also noted.  As previously indicated, this could 
be attributed to poor diffusion across the lumen.  It could also be attributed to reduced production 
of NO from the epithelial cells or even a reduction in nasal NO contamination. 
Discussion:  This study was not hypothesis-driven but instead, aimed to evaluate the 
previous research findings that suggested that exhaled carbon monoxide is increased in patients 
with inflammatory airway conditions.  The study design was limited in that it included very few 
patients with CF, despite the amount of participants. Utilizing patients with inflammatory airway 
disease is useful, although having more subjects with CF from which to collect data would 
strengthen the study.  Additionally, controlling for ambient levels would have further 
strengthened the results as to help reduce possible confounders that vary based upon where the 
participants live (rural vs. urban areas).  It is of note that it was really one of the first to suggest 
that exhaled CO was not increased in patients with CF. Contrary to these findings; several prior 
studies and reports had indicated that exhaled CO was increased in patients with upper 
respiratory tract infections.  This is important because it questioned whether or not exhaled CO 
could be used as a marker for airway inflammation and whether or not the methods in obtaining 
and assessing the measurements should be re-evaluated [31, 59, 62, 71, 74].   
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Of interesting note, the levels of CO did not appear to be flow-dependent, indicating that 
the airway epithelium does not contribute to the amount of CO in exhaled air, or else an increase 
in the concentration would be noted upon decrease airflow.   
4.3 EXHALED ETHANE IS ELEVATED IN CYSTIC FIBROSIS AND 
CORRELATES WITH CARBON MONOXIDE LEVELS AND AIRWAY 
OBSTRUCTION BY PAREDI, ET AL. 
Exhaled Ethane is Elevated in Cystic Fibrosis and Correlates with Carbon Monoxide 
Levels and Airway Obstruction by Paredi, et al., 1999.  This study looked at the volatile gas, 
ethane and compared it to levels of exhaled CO and NO [66]. 
Methods:  The researchers looked at 23 patients with CF, including 10 males and 13 
females, with a mean age of 21 years and mean FEV1 of 62 (4% of predicted).  Of these patients, 
10 were steroid treated; however, lung function was tested and was similar between the two 
patient populations.  All of the patients were tested for unusual CF pathogens like Burkholderia 
cepacia, methicillin-resistant Staphylococcus aureus and patients found to be colonized with 
these bacteria were excluded.  Patients with signs of symptoms of acute chest infection, 
pancreatic insufficiency or pulmonary exacerbation or a medical history of diabetes, lung cancer, 
liver disease or substance abuse were also excluded.  14 controls were used.  The subjects were 
tested and found to be non-smokers, and all of who were life-long non-smokers except for one 
patient who had quit one year prior to the study.  Any individuals with second-hand exposure to 
smoke (more than a half hour a day) were excluded.  Airway obstruction was measured by using 
residual volume and total lung capacity [66].   
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In order to help control for various ambient CO levels, each subject rested for an hour 
before testing.  End-tidal air was tested using gas chromatography for ethane.  CO was measured 
by electrochemical sensor and the mean of two measurements was taken with ambient CO levels 
subtracted from the values.  No was also measured and lung function tests were performed using 
spirometry on all of the subjects.     
Results:  The results showed that the levels of exhaled ethane were higher in the patients 
with CF that were not treated with steroids or the controls.  In patients with CF that were not 
treated with steroids, exhaled ethane levels correlated with CO concentrations and airway 
obstruction.  Exhaled CO levels were higher in patients that were not treated with steroids than 
those that were treated with steroids as well as the controls.  Exhaled NO levels did not appear to 
be affected by steroid treatment status and were lower in the patients with CF than in the 
controls.     
Conclusion:  This data and results are significant in that they further support the use of 
exhaled CO as a marker for oxidative stress and inflammation.  This is based upon the role of 
ethane as a marker for lipid peroxidation.  Since increased ethane levels correlated with 
increased levels of CO in CF patients not treated with steroids, this provides further evidence that 
exhaled CO is increased in patients with CF due to increases in oxidative stress.   
Discussion:  This study was very carefully designed to reduce the amount of possible 
confounders, including ambient gas levels, smoking status and age.  It was not hypothesis-driven 
but was designed to compare exhaled ethane with other markers of oxidative stress and 
inflammation (NO and CO) as well as compare the relationship between exhaled ethane and 
disease severity.  Separating patients based upon steroid-treatment status also was a strength of 
the study.  These results are consistent with the previous literature indicating that exhaled NO is 
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lower in patients with CF. These lower findings may reflect an increase in NO metabolites, or an 
inhibition of inducible NO synthase due to increased CO levels reducing overall production.  
Most importantly, this study may help establish a pattern of markers indicating that increased 
ethane and CO along with decreased NO may be used to help assess and monitor disease 
progression. 
4.4 INCREASED CARBON MONOXIDE IN EXHALED AIR OF PATIENTS WITH 
CYSTIC FIBROSIS BY PAREDI, ET AL. 
In the study entitled, “Increased carbon monoxide in exhaled air of patients with cystic 
fibrosis” by Paredi et al. done in 1999, exhaled CO was measured to determine if it can be used 
as a marker for airway inflammation and oxidative stress.   
Methods:  29 patients, including 15 men and 14 women with CF were studied to measure 
the levels of exhaled CO and NO concentrations.  Patients were tested for Burkholderia cepacia 
and methicillin resistant Staphylococcus aureus.  Any individuals found to be colonized with 
either of these were excluded from the study.  Additionally, any patients with severe respiratory 
infections or symptoms of exacerbation were also excluded.  The mean age of the patients with 
cystic fibrosis was 25 years, and they had on average an FEV of 43.  Of these 14 were being 
treated with steroids.  These patients were compared to a control group of 8 men and 7 women 
with a mean age of 31.  All of the subjects were tested and confirmed to be non-smokers and free 
of smoke exposure, and they all appeared to be free of pancreatic insufficiency.     
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A modified analyzer was used to measure the exhaled CO in the subjects.  The maximum 
value obtained from two breath exhalations was used and ambient CO levels were recorded prior 
to exhalation.  Exhaled NO was also measured using a chemiluminescence analyzer.   
Results:  The results of this study are summarized in the table below. (Table 8) 
 
Table 8. Results comparing Exhaled CO and NO levels in controls, CF patients (with and without steroid 
treatment and homo and heterozygous for the deltaF508 mutation)  
 
 
 
 
 
 
 
 
 
Conclusion: These findings support that exhaled CO is increased in patients with CF, 
which could reflect an increase in the amount of induced HO-1, which could be a direct result of 
oxidation and inflammation.  This theory is further supported by a reduction in exhaled CO 
measurements in patients that were treated with steroids.  This decrease in CO production could 
be attributed to the reduction in inflammation from steroid treatment.  This would lower the 
amount of oxidants released by inflammatory cells, and limit cytokine production, thereby 
decreasing the amount of HO-1 expressed.  Reduced HO-1 subsequently results in decreased 
production of CO, as seen in the steroid-treated subjects.  This study further supports the use of 
 Exhaled CO NO levels 
CF patients 6.7 (0.6) ppm 3.2 (0.2) ppb 
Controls 2.4 (0.4) ppm 6.8 (0.4) ppb 
CF w/ steroid 5.1 (0.5) ppm  
CF no steroids 8.4 (1.0) ppm  
dF508/dF508 7.7 (1.8) ppm 4.1 (0.5) ppb 
Heterozygous 4.0 (0.6) ppm 1.9 (0.7) ppb 
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CO a marker for airway inflammation [31]. This is of clinical importance because the 
measurement of exhaled CO may be useful to assess levels of oxidation and inflammation, which 
may allow us to better understand the pathophysiology as well as treat the progression of lung 
disease. 
Discussion:  This study was not hypothesis-driven, but instead was designed to further 
investigate whether levels of exhaled CO would be higher in patients with CF and whether the 
levels of exhaled CO and NO would be affected by the use of corticosteroids.  The separate 
analysis of patients who were treated with steroids and those who were not, greatly contributed 
to the strength of this study.  The use of ambient CO levels taken prior to each measurement also 
further strengthened the results by reducing potential confouners. 
4.5 END-TIDAL CARBON MONOXIDE CORRECTED FOR LUNG VOLUME IS 
ELEVATED IN PATIENTS WITH CYSTIC FIBROSIS BY TERHEGGEN-LAGRO, ET 
AL. 
The study entitled “End-Tidal Carbon Monoxide Corrected for Lung Volume Is Elevated 
in Patients with Cystic Fibrosis” conducted by Terheggen-Lagro, et al., in 2003 looked levels of 
exhaled end-tidal CO in order to determine if it is an appropriate marker for airway 
inflammation[71].   
Methods:  These researchers obtained twenty patients with CF who were considered to be 
clinically stable and thirty control subjects in order to compare the levels of end-tidal CO from 
exhaled breath.   
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Clinically stable was defined as not having any of the following: 
 Increase in sputum production 
 Increase in cough 
 Fever 
 Anorexia 
 Decline in lung function (FEV1) 
 
The patients had a mean age of 13.5 while controls were a mean age of 22.8.  All of the 
patients with CF were tested and found to have bacterial colonization of two of the most 
common bacterial infections, Pseudomonas aeruginosa and/or Staphylococcus aureus.  An 
electrochemical sensor was used to measure CO and H2 and end-tidal CO was measured, along 
with ambient CO levels after each measurement.  Airflow rates were used to help distinguish the 
origin of the ETCO (alveolar or bronchial).  Spirometry and plethysmography was used to 
measure lung functioning in the patients, while multiple-breath helium wash-in was used to help 
assess the lung volume in the controls.   
Results:    In this study, no significant increase/decrease in levels of ETCO was seen in 
patients with CF when compared to the healthy controls.  However when assessing the controls, 
there was a strong correlation between the ETCO and TLC-He levels.  When controls were 
compared to patients with CF, the levels of TLC-He were significantly lower in patients with CF, 
so the patients ETCO measurements were corrected for the TLC-He percent.  After this was 
completed, the patients with CF were found to have ETCO levels that were significantly higher 
than those of the controls.   
Conclusion:  This study was very significant in that although no difference was initially 
found in the ETCO levels of patients with CF and the controls, by studying physiologic factors 
that could affect ETCO, the following things were found.  Individuals with an increased lung 
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volume also had increases in ETCO.  When corrected for lung volumes, patients with CF had 
significantly higher levels of ETCO than controls.   
Discussion:  This study was designed to look at factors that influence end-tidal carbon 
monoxide levels in patients with CF. It is notable in that it hypothesized that increases in exhaled 
CO in patients with CF may be present but may not be evident upon initial exam due to 
differences in lung volumes between the subjects.  The design included adequate sample sizes 
with regard to cases and controls; however, it should be noted that the controls were on average 
almost a decade older than the cases.    
4.6  INCREASE IN EXHALED CARBON MONOXIDE DURING EXACERBATIONS 
OF CYSTIC FIBROSIS BY ANTUNI, ET AL. 
The study entitled “Increase in exhaled carbon monoxide during exacerbations of cystic 
fibrosis” by Antuni et al., was conducted in 2000 and looked at whether exhaled CO 
measurements were increased in CF patients with respiratory exacerbation as compared to those 
with clinically stable disease[59].   
Methods: The researchers looked at 44 patients with CF, some with clinically stable 
disease status and others who were considered to be in respiratory exacerbation, along with 12 
healthy controls (non-smokers).  They were studied in order to compare exhaled CO 
concentrations amongst the three populations to see if patients with exacerbation would have an 
increase in exhaled CO.  The average age of the controls was 37 years with FEV1 % predicted of 
95, and the average age of the CF patients was 29 with an FEV1 % predicted of 56.   
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The controls were individuals without respiratory disease who had also been clear of any 
upper or lower airway infections for at least a month prior to the start of the study.  They also 
needed to have normal spirometry levels.  Individuals for the CF patient population were 
screened for severe exacerbation, liver disease, haemolytic anaemia, and asthma.  Individuals 
with these conditions were excluded from the study.  Additionally, any smokers, individuals with 
upper airway infections within the past month, and patients unable of performing the exhaled 
breath measurement were also excluded.   
Respiratory exacerbation was defined as having at least one of the following symptoms: 
 Increased cough 
 Increased sputum 
 Change in sputum quality (more purulent, increased viscosity, presence of blood) 
 Sensation of increased chest congestion 
 Increased dyspnea 
 Decreased exercise tolerance 
 Worsening FEV1 
 
An electrochemical sensor was used to measure exhaled CO, along with NO and CO2.  The 
level of CO in the ambient air was recorded prior to each exhaled CO measurement.  Two 
measurements were used and the mean of the two measurements was used after subtracting the 
ambient CO level.  A t-test was used to compare the populations for statistical significance. 
Results:  Of the 44 patients with CF, 15 were considered to have exacerbations, while the rest 
were considered stable.  The results of exhaled CO are listed in parts per million and are based 
upon CF disease status (exacerbation vs stable) as compared to the controls.  Exacerbation was 
defined as having increased coughing, increased amount and change in quality of sputum, 
perceived shortness of breath and chest congestion as well as a decreased FEV1.  (Table 9) 
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 Table 9. Results of exhaled CO measurement comparing controls with CF patients in stable condition 
and with respiratory exacerbation.  
Subjects Exhaled CO in ppm 
Controls 2.0 
CF patients-stable 2.7 
CF –exacerbation 4.8 
 
 Conclusion:  The results of this study showed that levels of exhaled CO were higher in 
patients with CF than in controls and that within the patient population, individuals with signs 
and symptoms of respiratory exacerbation (as defined above) had significantly higher exhaled 
CO levels than that of patients who were considered clinically stable.  This is significant in that it 
indicates that exhaled CO can potentially be used to distinguish between patients who are 
clinically stable and patients who have disease exacerbation.   
Discussion:  This study was hypothesis-driven, with the working hypothesis having been 
that the HO-1 activity may be increased as a result of inflammation and oxidative stress in 
patients with CF who also had infective exacerbations, which would ultimately result in an 
increase in exhaled CO.  The findings supported this hypothesis, and the sample size of 44 
patients with CF was adequate.  The study was limited in that it did not separate patients who 
were being treated with steroids from those who were not being treated with steroids.  This 
additional information could potentially have strengthened the study design.   
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4.7 DISCUSSION OF OVERALL FINDINGS 
This literature review was originally intended to discuss the application of the exhaled 
gases CO and NO, in assessing airway inflammation in patients with cystic fibrosis.  Although 
CF has been researched and studied for decades, a surprising amount is still not fully elucidated 
or understood.  Over the past decades, medical advances have improved the quality and care of 
these patients, resulting in the significant increase in median survival and quality of life.  The 
specific mechanism by which CFTR mutations result in bacterial colonization and inflammation 
are still being dissected.  Overall, after reviewing the available literature and studies conducted 
on exhaled gas levels in patients with CF, the resulting patterns emerged.  The majority of 
evidence indicates that exhaled CO is, in fact, elevated in patients with CF and even further 
increased in patients with signs and symptoms of pulmonary exacerbation.  This increase in 
exhaled CO is attributed as a byproduct of heme catabolism, which is part of the inflammatory 
response and appears to be a result of oxidative stress. In addition, the majority of literature 
indicates that exhaled CO measurements are independent of airflow, suggesting that the CO from 
breath measurements is alveolar in origin and not from the bronchial airways, which is consistent 
with previous studies. [30, 31, 39, 47, 49, 56, 57, 59, 60, 62, 63, 65, 73-77].   
Furthermore, exhaled NO levels seem to be consistently decreased in patients with CF, 
which helps to further establish a pattern of high CO and low NO in patients with CF.  This can 
be used to help distinguish between inflammation, steroid treatment efficacy and also potentially 
be used in conjunction with other markers including volatile gases from exhaled breath (ethane) 
and 8-isoprostane to help establish additional biomarker patterns.  These patterns could 
potentially be used to differentiate between different disease severities and rates of progression, 
and allow us to assess inflammation prior to other clinical signs and symptoms of exacerbation, 
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perhaps allowing for earlier medical intervention and ultimately, reduce disease progression[42, 
64, 65, 70, 73].   
4.8 APPLICATION TO GENETIC COUNSELING AND PUBLIC HEALTH 
Genetic Counseling incorporates not only the genetic testing but also the management 
and follow-up of patients with genetic conditions.  Cystic Fibrosis, one of the most commonly 
inherited genetic conditions is certainly no exception.  Monitoring pulmonary disease status 
through non-invasive monitoring of airway inflammation is a critical component in the 
management and care of patients with Cystic Fibrosis.  As with all genetic conditions, genetic 
counselors should be familiar with the medical management of patients with CF. Additionally, 
the use of exhaled gas measurements could potentially help patients comply with airway 
clearance habits, as well as better predict pulmonary exacerbation and aid in the treatment of 
pulmonary infection, allowing for better patient care and overall improvement of well-being.  
The significant cost of medical care for these patients, in conjunction with the incidence of the 
disease and its chronically disabling nature warrant both continued research as well as public 
health priority.  Cystic Fibrosis has been studied for several decades but the need for continued 
research to better treat symptoms, manage disease, reduce and slow progression and ultimately 
develop a cure, is evident[4-6, 45].   
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5.0  EXHALED GAS STUDY 
As previously discussed, this literature review was conducted in context to a much larger 
exhaled gas study.  The exhaled gas study is a 3-phase study that is still currently underway and 
with which I have participated for the past two years in data collection.  The full IRB protocol is 
available for further review; however, it is much too extensive to include here.  The participating 
patients were selected based upon their ability to perform reliable PFTs and the majority was 
voluntarily consented prior to my participation, however I have consented patients after IRB 
updates were made to the original protocol.   Patients were recruited from both the pediatric and 
adult clinic from the University of Pittsburgh Medical Center and I obtained exhaled gas 
measurements from patients at two separate clinic sites, Falk Clinic in Oakland and the 
Children’s North Clinic in Wexford.   
Data collection has involved monitoring patient FEV1’s as well as obtaining exhaled CO 
measurements on the pediatric patients and exhaled CO, NO and CO2 measurements on the adult 
patients.  The primary goal of the study are to see if the levels of exhaled gas, primarily exhaled 
CO, can be used as markers for airway inflammation in patients with CF.  Tracking these levels 
both before patients get sick as well as when patients are sick in order to monitor them as they 
improve, will help provide further data to determine the clinical utility of exhaled gas.  These 
measurements may allow us to better monitor airway inflammation and exacerbation in patients 
and perhaps provide earlier indicators of bacterial infection and colonization or pulmonary 
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decline.  Earlier markers of exacerbation, colonization or pulmonary decline would enable us to 
begin earlier treatment and avoid more invasive monitoring techniques, which have long been 
the standard of care.   
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6.0  PERSONAL REFLECTION 
Participating in this research has provided me with a lot of insight in terms of caring for 
patients with this disease.  Working with both the pediatric and adult populations has allowed me 
to see the disparities between the needs of the patient populations, with disease progression being 
a primary factor.  Since this condition is chronically debilitating, I have established rapport with 
patients that have frequent clinic visits and have experienced first-hand some of the frustrations 
and emotional issues that come with chronic illness.   
Working with the pediatric patients I have seen how the disease affects the family 
dynamic, as parents are generally very involved in the care of their children.  This includes 
monitoring daily enzyme dosages, antibiotics, assisting and performing manual chest percussion 
for airway clearance, financial issues, taking time off for doctor’s appointments, transportation 
issues and a vast array of other issues and challenges that this disease causes.   
The adult patients still have some of the same concerns and issues, however they are 
facing additional challenges, including maintain weight, slowing lung disease progression, 
preserving lung function and ultimately fighting for increase survival.  Variation is disease 
severity is evident when some of these individuals are on disability and unable to work or do 
many of the things they would like to do, while others have full time jobs and physically active.    
The opportunity to work with this group of patients has provided me with greater insight 
with regard to the complex needs and unique concerns of this particular patient population.  It 
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has given a face to the numbers and statistics and many of these patients have forever touched 
my life with their struggles, their hope and ambition, their earnest pursuit for the things many 
people take for granted, like a breath of air.  These past two years of experience exposed me to 
the human side of the disease that medical texts and journal articles cannot possibly provide and 
have further instilled a passion to utilize the skills I’ve developed to better meet the needs of my 
future patients.   
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